1 / 32

ANFIM

ANFIM. Association of Needle Free Injection Manufacturers. ANFIM MISSION. The Mission of ANFIM is to promote and protect public health through the advancement of needle-free injection technology. ANFIM GOALS. Our Mission is achieved by the accomplishment of the following Goals:

lamya
Download Presentation

ANFIM

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ANFIM Association of Needle Free Injection Manufacturers

  2. ANFIM MISSION The Mission of ANFIM is to promote and protect public health through the advancement of needle-free injection technology. SIGN Conference

  3. ANFIM GOALS • Our Mission is achieved by the accomplishment of the following Goals: • Advocacy: Providing exposure, education, and information to the healthcare, pharmaceutical, and health insurance industries and to consumers. • Image: Creating a positive, professional image for the needle-free industry. • Information: Providing members with access to information regarding industry issues. SIGN Conference

  4. ANFIM MEMBERS • Class 1: Manufacturer • Antares Pharma (Mediject) - Bioject, Inc. • Equidyne Systems, Inc. - Keystone Industries • Class 2: Developer • DCI, Inc. - Felton International • Team Consulting Ltd. - PowderJect Vaccines • Class 3: Related Industry Members • Eli Lilly & Company - Novo Nordisk A/S • Class 4: Representatives from • Centers for Disease Control (CDC) • Program for Appropriate Technology in Health (PATH) • US Food and Drug Administration (FDA) SIGN Conference

  5. SIGN Conference

  6. SIGN Conference

  7. Needle Free Technology • What problems does it solve • Avoids needle stick hazard • No sharps disposal problems • Eliminates the concern for the re-use of needles • Injection pain is reduced in most cases • Speeds the injection cycle • Improved bio-availability of vaccines • Reduces the system cost of injection SIGN Conference

  8. Needle Free History • In use since 1947 • Military • International Public Health Campaigns • Widely used for mass immunizations and disease eradication. • Smallpox (1975) • Polio (when injected) • Measles (Brazil; 1990 to 1996) SIGN Conference

  9. Needle Free Requirements for the Developing World • Safety • Pathogen Transfer Issues • Disposal of Bio-Hazardous Material • Speed • High Thru-put • Ease of Use • Minimize training • Reduce repetitive motion injuries for health care workers • Simplify maintenance and spares logistics • Energy • Should be capable of being self powered • Cost • Must be comparable or less than traditional needle and syringe on a per injection basis SIGN Conference

  10. Review of the Industry • The following slides will provide a company by company review of the state of the art. SIGN Conference

  11. TEAM CONSULTINGwww.team-consulting.com • TEAM is one of the leading product development consultancies in the U.K., primarily serving the medical device and healthcare markets. • Developing CHEMOMOTOR • Motor Technology for Needle-free and Needled Auto-injectors • Low cost energy source • Tailored power profiles • Several thousand injections from a single filled device • Silent operation SIGN Conference

  12. SIGN Conference

  13. SIGN Conference

  14. PowderJectDNA Vaccines Advantages: • Direct Intracellular Delivery • 1,000-fold less DNA than Needle & Syringe delivery • Lower Cost • Safer • Elicits both Antibody and Cellular Responses • Potential for both Px and Rx products SIGN Conference

  15. PowderJectHepatitis B DNA Vaccination • PowderJect has achieved both antibody and cellular responses • PowderJect uses up to 2,500x lower dose PowderJect is the world leader in DNA vaccination SIGN Conference

  16. SIGN Conference

  17. Biojectwww.bioject.com • Biojector 2000 • Designed for the professional healthcare market • Immunization programs • Hospitals • Clinics • Self Injectors • Spring powered • CO2 powered with electronics SIGN Conference

  18. SIGN Conference

  19. Why Consider the Bioject Needle Free System ? • Proven Technology -- safer, faster, less invasive • Cost savings -- reduces expense of sharps waste disposal • Workforce Protection -- prevents dangerous and expensive needle stick injuries; meets new OSHA safety requirements • Clinical efficacy -- improves vaccine efficacy, faster onset of desired immune response • Operational Flexibility -- safely and quickly gives immunizations, even in non- clinical locations • Patient Compliance -- patients prefer needlefree over the needle and syringe SIGN Conference

  20. SIGN Conference

  21. from DCI, Inc. LectraJet HS (high speed) Jet Injection Kit (pat. pend.) For Mass Immunization Campaigns Funding provided byCenters for Disease Control and Prevention (SBIR Contract # 200-2000-10049) Linda D’Antonio, DCI, Inc. LindaD1@twcny.rr.com SIGN Conference

  22. LectraJet HS Key Requirements • Eliminate the risk of cross-infection • High Speed – up to 600 shots per hour SIGN Conference

  23. LectraJet HS • Single-use-auto-disable Ampules • DCI Ampule Management System • Rapid retrieval and ejection of Ampules • No contact with Ampule before or after shot • On-site Ampule filling system • Electrical or Manual Power • Complete injection Kit SIGN Conference

  24. SIGN Conference

  25. SIGN Conference

  26. SIGN Conference

  27. SIGN Conference

  28. Issues for Campaigns • Safety • Eliminate risk of pathogen transfer • Re-use of needles • Nozzle contamination • Eliminate sharps disposal • Speed • Up to 600 injections per hour • Cost • Comparable or less than the cost of needle and syringe systems SIGN Conference

  29. Thank You ANFIM

  30. SIGN Conference

  31. New York City School Survey fdfdfas fdsfsaf fdafdsfas ggdfsf fdfdfas fdsfsaf fdafdsfas ggdfsf fdfdfas fdsfsaf fdafdsfas ggdfsf SIGN Conference

  32. Oklahoma Preference Survey Graph 2: Clients receiving multiple injection only. Were you satisfied with your needle-free injection method? No = 3% Don't Know Yes = 87% = 10% Results from those clients receiving multiple injections with the Biojector were tabulated, showing an 87% satisfaction rating for the needle-free system. SIGN Conference

More Related